glp 1 cardiovascular risk Are you on an GLP-1 agonist like Wegovy? Zepbound? The craze is real. The data is strong. The heart is protected Cardiovascular Risks after GLP-1 Discontinuation

Diabetes Therapy, 2021 A meta-analysis of cardiovascular outcomes trials showing that GLP-1 receptor agonists improve heart health in patients with type 2 diabetes, with dosing levels influencing tolerability and side effect profiles

Pharm Res 37 , 120 (2020)

Importantly, meta-analyses of randomized controlled trials have generally not shown a statistically significant increased risk of pancreatitis with GLP-1 receptor agonists as a class

A brief history of nearly EV-erything - the rise and rise of extracellular vesicles

Das ist besonders hilfreich bei hormonellen Vernderungen wie in der Schwangerschaft oder whrend der Menopause